You are here: Industry Insights > VMS

News List

Astellas’ non-hormonal VMS therapy gets FDA approval SHEM OIRERE
June 08, 2023
U.S. Food and Drug Administration has approved Veozah, the first neurokinin 3 receptor antagonist, to treat moderate to severe vasomotor symptoms.
Chime Biologics Announced the Completion of US$190 Million Series A+ Financing to Accelerate Capacity Expansion prnasia
March 26, 2021
Chime Biologics, a China-based, world-class CDMO company, announced today that it has secured a total commitment of US$190 million investment from institutional investors, and over $100 million investment has already been closed today.
Millendo Therapeutics initiates first-in-human clinical trial of MLE-301 pharmaceutical-business-review
September 30, 2020
Millendo Therapeutics announced dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301 ...
Breast Cancer Incidence Up With Persistent Vasomotor Symptoms drugs
January 15, 2019
Postmenopausal women with persistent vasomotor symptoms (VMS) have an increased incidence of breast cancer, according to a study published online Dec. 28 in Menopause.....